Article Sidebar
Views pdf: 0
APPLICATION OF HUMAN PAPILLOMA VIRUS mRNA TESTING ON GYNECOLOGICAL PATIENTS AT HAI PHONG OBSTETRICS AND GYNECOLOGY HOSPITAL IN 2024
Main Article Content
Abstract
Objectives: 1. To describe the current status of gynecological patients diagnosed with HPV infection using mRNA-based techniques at Hai Phong Obstetrics and Gynecology Hospital in 2024. 2. To evaluate the results of HPV mRNA testing in diagnosing HPV infection and associated factors among these patients. Sample size: A convenience sampling approach was employed. A total of 1079 participants who met the inclusion and exclusion criteria were enrolled during the study period from June 1, 2024 to December 31, 2024 at Hai Phong Obstetrics and Gynecology Hospital. Participants were recruited based on their availability and presentation for gynecological care within the specified timeframe. Study design: Cross-sectional descriptive study. Results and conclusions: The mean age of participants was 38.54 ± 10.23 years. A history of cervical intervention was reported in 4.6% of cases. Cytology results showed 0.5% with HSIL and 0.4% with LSIL. Colposcopy findings included normal cervix (54.7%), cervicitis (35.9%), acetowhite lesions (0.7%), and cervical fibroids (0.1%). The HPV infection rate was 10%, with the 12 high-risk genotypes accounting for the highest proportion (6.8%). HPV 16 and HPV 18 were detected in 2.4% and 0.8% of cases, respectively. Co-infection with HPV 16 and other 12 high-risk types was found in one woman (0.1%). Patients with a history of cervical intervention had a 37.7-fold higher risk of HPV infection compared to those without such history (p < 0.001). The HPV-positive group had a 19.4-fold higher rate of dysplastic lesions on colposcopy compared to the HPV-negative group. Stratified by risk, patients infected with HPV types 16 and/or 18 had a 4.76-fold higher rate of dysplastic colposcopic findings compared to those infected with the other 12 high-risk types. The rate of abnormal cytology was 78.46 times higher in the HPV-positive group than in the HPV-negative group. Additionally, those infected with HPV 16 and/or 18 had an 8.75-fold higher rate of abnormal cytology compared to those infected with the other 12 high-risk types.
Article Details
Keywords
HPV, mRNA
References
2. Zhang S. K et al (2020). The potential benefits of HPV E6/E7 mRNA test in cervical cancer screening in China. Front Oncol. 10.3389/fonc. 2020.533253.
3. Trần Thị Ngọc Linh (2017). Nhận xét kết quả xét nghiệm bộ đôi HR-HPV và tế bào học cổ tử cung tại khoa khám bệnh - Bệnh viện Phụ sản Hà Nội. Luận văn Thạc sỹ y học.
4. Lâm Đức Tâm (2013). Nghiên cứu tỷ lệ nhiễm Human Papilloma Virus và các yếu tố liên quan tổn thương tiền ung thư cổ tử cung ở phụ nữ từ 18- 60 tuổi. Y học Thành phố Hồ Chí Minh, vol. tập 17(1), tr. 213- 220
5. Center M. A. C (2021). LEEP procedure: 8 common questions answered.
6. Depuydt C. E, Leuridan E, Van Damme P et al (2010). Epidemiology of Trichomonas vaginalis and human Papillomavirus infection detected by real-time PCR in flanders. Gynecol Obstet Invest. 10.1159/000314017.
7. Phan Thị Thanh Lan, Vũ Văn Tâm, Lưu Vũ Dũng (2017). Nghiên cứu tỷ lệ nhiễm HPV ở bệnh nhân có tổn thương cổ tử cung tại Bệnh viện Phụ Sản Hải Phòng bằng kỹ thuật Real - time PCR và Reverse Dot blot hybridization. Tạp chí Phụ Sản, tập 15, số 2.
8. Li H, Li P, Huang L et al (2020). Prevalence characteristics of cervical human Papillomavirus (HPV) infection in the Zhoupu District, Shanghai City, China," Virology Journal. 10.1186/s12985-020-01352-8.
9. Chen X et al (2017). Prevalence and genotype distribution of human Papillomavirus in 961,029 screening tests in southeastern China (Zhejiang Province) between 2011 and 2015. Sci Rep. 10.1038/s41598-017-13299-y.